Guardant Health reaches record highs as bullish patterns align across timeframes, opening potential upside toward $250 if buyers defend key breakout support.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results from the COSMOS-MEL01 study (UMIN000042040). The study is the first published prospective, multicenter evaluation of the tissue-free, epigenomic Guardant Reveal™ blood test for molecular residual disease (MRD) detection and recurrence monitoring in patients wi.
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation. Analyst Ratings This is a summary of
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
CorVel (NASDAQ: CRVL - Get Free Report) and Guardant Health (NASDAQ: GH - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Risk and Volatility CorVel has a beta of 0.97,
Earning a spot on the IBD Leaderboard and IBD 50, Guardant Health stress tests a breakout.
Guardant Health (NASDAQ: GH - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings. Earnings and Valuation This table compares Guardant Health and
Guardant Health, Inc. (NASDAQ: GH - Get Free Report) Director Alex Azar II sold 826 shares of Guardant Health stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the sale, the director owned 825 shares of the
Guardant Health, Inc. (GH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per ACS guidelines. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country spanning more than 23 states. The latest policy update from Shield marks a rapid growth in commercial adopt.
